BRPI0608148A2 - [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso - Google Patents

[3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso

Info

Publication number
BRPI0608148A2
BRPI0608148A2 BRPI0608148-7A BRPI0608148A BRPI0608148A2 BR PI0608148 A2 BRPI0608148 A2 BR PI0608148A2 BR PI0608148 A BRPI0608148 A BR PI0608148A BR PI0608148 A2 BRPI0608148 A2 BR PI0608148A2
Authority
BR
Brazil
Prior art keywords
transport inhibitors
pharmaceutical composition
type
glycine transport
disorder treatment
Prior art date
Application number
BRPI0608148-7A
Other languages
English (en)
Inventor
Stanton Furst Mchardy
John Adams Lowe Iii
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0608148A2 publication Critical patent/BRPI0608148A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

[3.1.01] HETEROARIL AMIDAS BICìCLICAS COMO INIBIDORES DE TRANSPORTE DE GLICINA DO TIPO I, COMPOSIçãO FARMACêUTICA PARA TRATAMENTO DE DISTúRBIOS E SEU USO. A presente invenção refere-se a uma série de [3.1.0] heteroaril amidas bicíclicas substituídas da Fórmula I, em que os grupos A, Q, X, 1, Z e R~ 1~-R~ 5~ são definidos como io relatório descritivo, que exibem atividade como inibidores de transporte dE glicina, seus sais farmaceuticamente aceitáveis, as composições farmacêuticas que as contêm, e seu uso para o aumento da cognição e o tratamento dos sintomas positivos e negativos de esquizofrenia e outras psicoses em mamíferos, incluindo seres humanos.
BRPI0608148-7A 2005-04-08 2006-03-27 [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso BRPI0608148A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66947205P 2005-04-08 2005-04-08
PCT/IB2006/000947 WO2006106425A1 (en) 2005-04-08 2006-03-27 Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors

Publications (1)

Publication Number Publication Date
BRPI0608148A2 true BRPI0608148A2 (pt) 2009-11-10

Family

ID=36649611

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608148-7A BRPI0608148A2 (pt) 2005-04-08 2006-03-27 [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso

Country Status (31)

Country Link
US (2) US20060229455A1 (pt)
EP (1) EP1869019B1 (pt)
JP (1) JP4193949B2 (pt)
KR (1) KR100969402B1 (pt)
CN (1) CN101189228A (pt)
AP (1) AP2007004198A0 (pt)
AR (1) AR056307A1 (pt)
AU (1) AU2006231917B2 (pt)
BR (1) BRPI0608148A2 (pt)
CA (1) CA2603939C (pt)
CR (1) CR9493A (pt)
DK (1) DK1869019T3 (pt)
DO (1) DOP2006000078A (pt)
EA (1) EA014311B1 (pt)
ES (1) ES2520015T3 (pt)
GE (1) GEP20105053B (pt)
GT (1) GT200600136A (pt)
HN (1) HN2006013804A (pt)
IL (1) IL186409A (pt)
MA (1) MA29672B1 (pt)
MX (1) MX2007012463A (pt)
NL (1) NL1031539C2 (pt)
NO (1) NO339422B1 (pt)
NZ (1) NZ563238A (pt)
PE (1) PE20061400A1 (pt)
TN (1) TNSN07380A1 (pt)
TW (1) TW200719890A (pt)
UA (1) UA88518C2 (pt)
UY (1) UY29456A1 (pt)
WO (1) WO2006106425A1 (pt)
ZA (1) ZA200708481B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP2344470B1 (en) * 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
EP2409976A4 (en) * 2009-03-19 2012-09-19 Taisho Pharmaceutical Co Ltd GLYCINE TRANSPORTER INHIBITOR
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AR077472A1 (es) * 2009-07-15 2011-08-31 Taisho Pharmaceutical Co Ltd Inhibidores de transportador de glicina
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
JP2013249257A (ja) * 2010-09-16 2013-12-12 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
WO2012036278A1 (ja) 2010-09-17 2012-03-22 大正製薬株式会社 グリシントランスポーター阻害物質
JP2013249258A (ja) * 2010-09-17 2013-12-12 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
EP2909181B1 (en) * 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
KR20210141621A (ko) 2019-03-22 2021-11-23 스미토모 다이니폰 파마 온콜로지, 인크. Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058684A1 (en) 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
JP2002212179A (ja) 2001-01-15 2002-07-31 Wakunaga Pharmaceut Co Ltd 新規アニリド誘導体又はその塩及びこれを含有する医薬
US20050228017A1 (en) 2001-10-31 2005-10-13 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel anticancer compounds
FR2838739B1 (fr) 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
RS20060190A (sr) * 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
EP3461813A1 (en) 2004-05-23 2019-04-03 Gerard M. Housey Theramutein modulators

Also Published As

Publication number Publication date
ZA200708481B (en) 2010-05-26
UY29456A1 (es) 2006-11-30
JP4193949B2 (ja) 2008-12-10
AR056307A1 (es) 2007-10-03
KR100969402B1 (ko) 2010-07-14
IL186409A (en) 2012-07-31
NZ563238A (en) 2011-01-28
EA014311B1 (ru) 2010-10-29
CR9493A (es) 2007-12-04
IL186409A0 (en) 2008-01-20
PE20061400A1 (es) 2007-01-15
TNSN07380A1 (fr) 2009-03-17
WO2006106425A1 (en) 2006-10-12
AU2006231917B2 (en) 2011-07-28
HN2006013804A (es) 2009-10-30
CA2603939A1 (en) 2006-10-12
ES2520015T3 (es) 2014-11-11
NO20074993L (no) 2007-11-02
US8124639B2 (en) 2012-02-28
MA29672B1 (fr) 2008-08-01
AP2007004198A0 (en) 2007-10-31
EA200701902A1 (ru) 2008-04-28
NL1031539A1 (nl) 2006-10-10
US20100324020A1 (en) 2010-12-23
CA2603939C (en) 2013-08-27
EP1869019A1 (en) 2007-12-26
NL1031539C2 (nl) 2007-04-10
DOP2006000078A (es) 2006-10-15
GEP20105053B (en) 2010-07-26
MX2007012463A (es) 2007-11-07
US20060229455A1 (en) 2006-10-12
TW200719890A (en) 2007-06-01
EP1869019B1 (en) 2014-08-27
UA88518C2 (ru) 2009-10-26
CN101189228A (zh) 2008-05-28
DK1869019T3 (da) 2014-10-06
KR20070120582A (ko) 2007-12-24
AU2006231917A1 (en) 2006-10-12
JP2008534671A (ja) 2008-08-28
NO339422B1 (no) 2016-12-12
GT200600136A (es) 2006-11-07

Similar Documents

Publication Publication Date Title
BRPI0608148A2 (pt) [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso
BRPI0415356A (pt) derivados bicìclicos [3.1.0] como inibidores do transportador de glicina
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BRPI0911444B8 (pt) benzoimidazóis como inibidores de prolil hidroxilase e composição farmacêutica que os compreende
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
BRPI0908353B8 (pt) composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica
BRPI0719195B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
BR112012029395A2 (pt) lactamas piperdinil-substituídas como moduladores de gpr119
ECSP088762A (es) Tratamiento del dolor
BR112013032391A2 (pt) antagonistas de trpv4
BR112012018098A2 (pt) compostos de 4-fenoxi-nicotinamida ou 4-fenoxi-pirimidina -5-carboxamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013.